未登录 分享 收藏
Single-cell transcriptomics of melanoma sentinel lymph nodes identifies immune cell associated with metastasis 黑色素瘤哨兵淋巴结的单细胞转录组学鉴定了与转移相关的免疫细胞 Engelbrecht, Eric; Stamp, Bryce F.; Chew, Lewis; Sarkar, Omar Sadi; Harter, Phillip; Waigel, Sabine J.; Rouchka, Eric C.; Chariker, Julia; Smolenkov, Andrei; Chesney, Jason; McMasters, Kelly; Watson, Corey T.; Yaddanapudi, Kavitha 分享 收藏
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients Robert, C.; Long, G. V.; Larkin, J.; Wolchok, J. D.; Hassel, J. C.; Schadendorf, D.; Hodi, F. S.; Lebbe, C.; Grob, J. -j.; Hyngstrom, J. R.; Wagstaff, J.; Chesney, J.; Butler, M. O.; Bechter, O.; Marquez-Rodas, I.; Pavlick, A. C.; Durani, P.; Benito, M. Pe; Wang, P.; Postow, M. A.; Ascierto, P. A. 分享 收藏
分享 收藏
Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti - PD-1 therapy: MASTERKEY-115, 1,2 Robert, Caroline; Gastman, Brian; Gogas, Helen; Rutkowski, Piotr; V. Long, Georgina; Chaney, Marya F.; Joshi, Harshada; Lin, Yu-Lin; Snyder, Wendy; Chesney, Jason A. 分享 收藏
TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma TILVANCE-301，lifileucel肿瘤浸润淋巴细胞 (TIL) 细胞疗法联合pembrolizumab与单独pembrolizumab治疗初治不可切除或转移性黑色素瘤的3期研究 Thomas, Sajeve; Hong, Young Ki; Samhouri, Yazan; Larkin, James; Olson, David J.; In, Gino K.; Atkinson, Victoria; Lammers, Philip; Furness, Andrew J.; Martin-Liberal, Juan; Terheyden, Patrick; Poklepovic, Andrew S.; Nguyen, Ryan H.; Peretz, Idit; Butler, Marcus; Khattak, Adnan; Spain, Lavinia; Gaughan, E. M.; Wilson, Melissa; Dubay, John W.; Williams, Anja; Goff, Stephanie; Doolittle, Gary C.; Chesney, Jason; Finckenstein, Friedrich Graf; Chou, Jeffrey; Wu, Xiao; Sulur, Giri; Shi, Wen; Haanen, John 分享 收藏
Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma Thomas, Sajeve S.; Chesney, Jason A.; Hamid, Omid; In, Gino K.; Shoushtari, Alexander N.; Samhouri, Yazan; Hari, Parameswaran; Ramsingh, Giridharan; Prabhakar, Prakash; Mclaughlin, Lauren; Warner, Allison Betof 分享 收藏
Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study Grigoleit, G. U.; Kluger, H.; Thomas, S.; Chesney, J. A.; Domingo-Musibay, E.; Sanmamed, M. F.; Medina, T.; Ziemer, M.; Whitman, E.; Finckenstein, F. Graf; Chou, J.; Wu, X.; Sulur, G.; Shi, W.; Sarnaik, A. 分享 收藏
Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy Sarkar, Omar S.; Donninger, Howard; Al Rayyan, Numan; Chew, Lewis C.; Stamp, Bryce; Zhang, Xiang; Whitt, Aaron; Li, Chi; Hall, Melissa; Mitchell, Robert A.; Zippelius, Alfred; Eaton, John; Chesney, Jason A.; Yaddanapudi, Kavitha 分享 收藏
分享 收藏
分享 收藏
分享 收藏
A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC Chesney, J.; Wise-Draper, T.; Sarnaik, A. A.; Finckenstein, F. Graf; Hari, P.; Jagasia, M.; Desai, A.; Suzuki, A.; Wu, X.; Warner, A. Betof 分享 收藏
分享 收藏
分享 收藏
Biomarker analysis from a phase Ib, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors Hecht, J. R.; Peeters, M.; Jimenez, M. Martin; Pless, M.; Cubillo, A.; Garcia-Corbacho, J.; Mach, N.; Digklia, A.; Park, H.; Subbiah, V.; Gorski, K.; Anderson, A.; Liu, C.; Snyder, W.; Chesney, J. 分享 收藏
IGNYTE: AN OPEN-LABEL, MULTICENTER, PHASE 1/2 (PH 1/2) CLINICAL TRIAL OF RP1 ± NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS Middleton, Mark; Milhem, Mohammed; Aroldi, Francesca; Sacco, Joseph; VanderWalde, Ari; Baum, Scott; Samson, Adel; Chesney, Jason; Niu, Jiaxin; Rhodes, Terence; Bowles, Tawnya; Emamekhoo, Hamid; Tsai, Katy; In, Gino; Beasley, Georgia; Chmielowski, Bartosz; Dalac-Rat, Sophie; Kahler, Katharina; Munoz, Eva; Olsson-Brown, Anna; Bommareddy, Praveen; Menezes, Lavita; Pirzkall, Andrea; Coffin, Robert; Harrington, Kevin 分享 收藏
MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL) MASTERKEY-265: talimogene laherparepvec (T) 联合pembrolizumab (P) 治疗不可切除期IIIB-IVM1c黑色素瘤 (MEL) 的III期随机安慰剂 (Pbo) 对照研究 Ribas, A.; Chesney, J.; Long, G. V.; Kirkwood, J. M.; Dummer, R.; Puzanov, I.; Hoeller, C.; Gajewski, T. F.; Gutzmer, R.; Rutkowski, P.; Demidov, L.; Arenberger, P.; Shin, S. J.; Ferrucci, P. F.; Diede, S. J.; Anderson, J. R.; Treichel, S.; Chan, E.; Hodi, F. S.; Gogas, H. J. 分享 收藏
An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE] Aroldi, F.; Middleton, M. R.; Sacco, J. J.; Milhem, M. M.; Curti, B. D.; VanderWalde, A. M.; Baum, S. L.; Samson, A.; Chesney, J.; Niu, J.; Rhodes, T. D.; Bowles, T. L.; Olsson-Brown, A.; Laux, D. E.; Bommareddy, P. K.; Menezes, L.; Samakoglu, S.; Pirzkall, A.; Coffin, R. S.; Harrington, K. J. 分享 收藏
分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
CANCER RESEARCH.png)
.png){kind=icon}
分享.png){kind=icon}
收藏
OAAI